SynthesisJournal of clinical pharmacology2021

A Population Pharmacokinetic Meta-Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients.

Sven Stodtmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.